Cargando…
Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson's disease
Parkinson's disease (PD) results from the degeneration of dopaminergic neurons in the substantia nigra and the consequent deficit of dopamine released in the striatum. Current oral dopamine replacement or surgical therapies do not address the underlying issue of neurodegeneration, they neither...
Autores principales: | Falk, Torsten, Zhang, Shiling, Sherman, Scott J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2799405/ https://www.ncbi.nlm.nih.gov/pubmed/20003314 http://dx.doi.org/10.1186/1750-1326-4-49 |
Ejemplares similares
-
Insights into the Mechanisms Involved in Protective Effects of VEGF-B in Dopaminergic Neurons
por: Caballero, Beatrice, et al.
Publicado: (2017) -
VEGF(121)b and VEGF(165)b are weakly angiogenic isoforms of VEGF-A
por: Catena, Raúl, et al.
Publicado: (2010) -
The Yin and Yang of VEGF and PEDF: Multifaceted Neurotrophic Factors and Their Potential in the Treatment of Parkinson’s Disease
por: Falk, Torsten, et al.
Publicado: (2010) -
The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy
por: Pożarowska, Dorota, et al.
Publicado: (2016) -
Binding of VEGF-A is sufficient to abrogate the disturbing effects of VEGF-B together with VEGF-A on retinal endothelial cells
por: Deissler, Heidrun L., et al.
Publicado: (2015)